Literature DB >> 17435987

[Thrombolysis for ischemic stroke: an update].

M Köhrmann1, E Jüttler, H B Huttner, P D Schellinger.   

Abstract

Even 10 years after the approval of thrombolysis this life-saving and disability reducing therapy is still underused. Important reasons for that are very strict inclusion criteria such as the early and narrow time-window, fear of bleeding complications and doubts regarding the effectiveness. An intensive and constant effort is required to educate the public that stroke is a treatable emergency. In addition to the medical reasons, economic considerations in a context of decreasing resources emphasize the importance of effective stroke treatment. The results of numerous recent studies such as the European register SITS-MOST help to strengthen the confidence in thrombolysis. In addition the development and advancement of new imaging tools such as multiparametric MRI and advanced CT-techniques will improve patient selection and may enable us to extend the time-window for treatment. Intraarterial thrombolysis, "bridging" methods and new devices for intravascular intervention are the subjects of intensive ongoing research. Even though no randomized trials are available intraarterial thrombolysis is the treatment of choice for acute basilar occlusion, but if this intervention is not available an intravenous approach may be an equal alternative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435987     DOI: 10.1007/s00115-006-2246-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  47 in total

1.  Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002.

Authors:  Brian T Bateman; H Christian Schumacher; Bernadette Boden-Albala; Mitchell F Berman; J P Mohr; Ralph L Sacco; John Pile-Spellman
Journal:  Stroke       Date:  2006-01-05       Impact factor: 7.914

2.  Cost-effectiveness analysis of thrombolytic treatment for stroke.

Authors:  Javier Mar; Jose Maria Begiristain; Arantza Arrazola
Journal:  Cerebrovasc Dis       Date:  2005-07-27       Impact factor: 2.762

3.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.

Authors:  Anthony J Furlan; Dirk Eyding; Gregory W Albers; Yasir Al-Rawi; Kennedy R Lees; Howard A Rowley; Christian Sachara; Mariola Soehngen; Steven Warach; Werner Hacke
Journal:  Stroke       Date:  2006-03-30       Impact factor: 7.914

4.  A pilot study of a new thrombolytic agent for acute ischemic stroke in Taiwan within a five-hour window.

Authors:  Han-Hwa Hu; Michael Mu-Huo Teng; Li-Chi Hsu; Wen-Jang Wong; Lee-Min Wang; Yun-On Luk; Chang-Ming Chern; Bing-Wen Soong; Wen-Yung Sheng
Journal:  Stroke       Date:  2006-01-19       Impact factor: 7.914

5.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Authors:  Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

6.  [Stroke treatment in the 2006 German diagnosis-related group system].

Authors:  N Roeder; W Fiori; E B Ringelstein
Journal:  Nervenarzt       Date:  2006-02       Impact factor: 1.214

7.  Outcome in patients with basilar artery occlusion treated conventionally.

Authors:  W J Schonewille; A Algra; J Serena; C A Molina; L J Kappelle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

8.  Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Authors:  Timothy John Ingall; William Michael O'Fallon; Kjell Asplund; Lewis Robert Goldfrank; Vicki S Hertzberg; Thomas Arthur Louis; Teresa J Hengy Christianson
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

9.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

10.  NXY-059 for acute ischemic stroke.

Authors:  Kennedy R Lees; Justin A Zivin; Tim Ashwood; Antonio Davalos; Stephen M Davis; Hans-Christoph Diener; James Grotta; Patrick Lyden; Ashfaq Shuaib; Hans-Göran Hårdemark; Warren W Wasiewski
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

View more
  2 in total

1.  Neurointerventional treatment of amphetamine-induced acute occlusion of the middle cerebral artery by intracranial balloon angioplasty.

Authors:  B Loewenhardt; M Bernhard; A Pierskalla; T Neumann-Haefelin; E Hofmann
Journal:  Clin Neuroradiol       Date:  2011-12-16       Impact factor: 3.649

2.  Penumbra Stroke System as an "add-on" for the treatment of large vessel occlusive disease following thrombolysis: first results.

Authors:  Tobias Struffert; Martin Köhrmann; Tobias Engelhorn; Tim Nowe; Gregor Richter; Peter D Schellinger; Stefan Schwab; Arnd Doerfler
Journal:  Eur Radiol       Date:  2009-04-07       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.